English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 55208/89501 (62%)
造訪人次 : 10716726      線上人數 : 24
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/41652


    題名: Glycine transporter-1 inhibitor, N-methyglycine (sarcosine), added to clozapine for the treatment of schizophrenia
    作者: Lane, Hsien-yuan;Huang, Chieh-liang;Wu, Po-lun;Liu, Yi-ching;張玉坤;Chang, Yue-cune;張玉坤;Lin, Pao-yen;Chen, Po-wei;Tsai, Guochuan
    貢獻者: 淡江大學數學學系
    關鍵詞: Glutamate;GlyT-1;N-methyl-D-aspartate;sarcosine;schizophrenia;treatment
    日期: 2006-09-15
    上傳時間: 2010-01-28
    出版者: Elsevier
    摘要: Background

    Agonists at the N-methyl-D-aspartate (NMDA)-glycine site (D-serine, glycine, D-alanine and D-cycloserine) and glycine transporter-1 (GlyT-1) inhibitor (N-methylglycine, or called sarcosine) both improve the symptoms of stable chronic schizophrenia patients receiving concurrent antipsychotics. Previous studies, however, found no advantage of D-serine, glycine, or D-cycloserine added to clozapine. The present study aims to determine the effects of sarcosine adjuvant therapy for schizophrenic patients receiving clozapine treatment.

    Methods

    Twenty schizophrenic inpatients enrolled in a 6-week double-blind, placebo-controlled trial of sarcosine (2 g/day) which was added to their stable doses of clozapine. Measures of clinical efficacy and side-effects were determined every other week.

    Results

    Sarcosine produced no greater improvement when co-administered with clozapine than placebo plus clozapine at weeks 2, 4, and 6. Sarcosine was well tolerated and no significant side-effect was noted.

    Conclusions

    Unlike patients treated with other antipsychotics, patients who received clozapine treatment exhibit no improvement by adding sarcosine or agonists at the NMDA-glycine site. Clozapine possesses particular efficacy, possibly related to potentiation of NMDA-mediated neurotransmission. This may contribute to the clozapine’s unique clinical efficacy and refractoriness to the addition of NMDA-enhancing agents.
    關聯: Biological Psychiatry 60(6), pp.645-649
    DOI: 10.1016/j.biopsych.2006.04.005
    顯示於類別:[數學學系暨研究所] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    0KbUnknown276檢視/開啟
    index.html0KbHTML2檢視/開啟

    在機構典藏中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋